COMPANY

LTZ Therapeutics

HQ: Redwood City, CA (US office) source · ltztherapeutics.com ↗ · West Coast

Keywords: oncology immunology autoimmune diseases Non-Hodgkin Lymphoma Refractory/ Relapsed DLBCL - Diffuse Large B Cell Lymphoma Mantle Cell Lymphoma Follicular Lymphoma Marginal Zone Lymphoma LTZ-301

Location: Redwood City, CA (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Raises and deals from press releases

Raise Undisclosed round · $38M · announced May 6, 2026 Company release ↗
Source quote
- May 6, 2026 · Company release ↗
  “– LTZ Therapeutics , a clinical-stage, immunotherapy-focused biotechnology company, today announced the completion of an oversubscribed $38 million financing round to accelerate development of its Universal Myeloid Cell Engager (U-MCE TM )-based immunotherapy pipeline”
Deal GSK deal · amount not disclosed · announced Nov 19, 2025 Company release ↗
Source quote
- Nov 19, 2025 · Company release ↗
  “LTZ … Therapeutics (LTZ), an immunotherapy-focused biotechnology company based in Redwood City, California, today announced a strategic research collaboration to advance the development of novel myeloid cell engagers (MCEs) to address significant unmet need in oncology.”
Deal Eli Lilly deal · amount not disclosed · announced Jul 29, 2025 Company release ↗
Source quote
- Jul 29, 2025 · Company release ↗
  “Collaboration combines LTZ’s first-in-class Myeloid Engager Platform with Lilly’s world-class expertise in research, development and commercialization REDWOOD CITY, California and SHENZHEN, China – July 29, 2025 – LTZ Therapeutics ("LTZ")”
Raise Series A · more than $20M · announced Jul 30, 2024 Company release ↗
Source quote
- Jul 30, 2024 · Company release ↗
  “– LTZ Therapeutics , an immunotherapy-focused biotech company, today announced the completion of the company’s Series A financing of over $20 million, to advance the development of its Myeloid Engager pipeline to treat cancer and autoimmune diseases”

Raises announced in these releases: $58M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

May 6, 2026 Raise Undisclosed round · $38M source ↗
Jan 29, 2026 Trial start 1: This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma source ↗
Jul 29, 2025 Partnership Partnership / licensing announced Jul 29, 2025. Source: company's own press page. source ↗
Jul 30, 2024 Raise Series A · more than $20M source ↗

Upcoming milestones

2028-02 (ESTIMATED) · 1 · This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma · NCT07121946

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Jul 29, 2025 Partnership / licensing announced Jul 29, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07121946	This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma	1	Recruiting	Jan 29, 2026	2028-02 (estimated)